Literature DB >> 15841187

The Role of High-Potency Benzodiazepines in the Treatment of Panic Disorder.

Jeffrey Susman1, Brian Klee.   

Abstract

Medication plays a central role in the treatment of panic disorder, with the goal of eliminating panic attacks and restoring normal function (i.e., achieving full remission). Four drug classes have similar efficacy (tricyclic antidepressants, selective serotonin reuptake inhibitors [SSRIs], benzodiazepines, and monoamine oxidase inhibitors). Nonetheless, benzodiazepines remain the most prescribed medication for panic disorder in the United States. The high-potency benzodiaze-pines alprazolam (available as immediate- and extended-release tablets) and clonazepam (available as tablets and orally disintegrating wafers) are the only benzodiazepines approved by the U.S. Food and Drug Administration for the treatment of panic disorder. High-potency benzodiaze-pines, with their proven efficacy in panic disorder exerted through control of the central nervous system excitability by a selective and potent enhancement of inhibitory gamma-aminobutyric acid-mediated neurotransmission, are also a safe and well-tolerated option for potentiation of rapid treatment response when initiating treatment with SSRIs. Judicious use of high-potency benzodiazepines followed by a cautious taper and discontinuation may optimize the benefits and minimize any potential risk associated with this class of drugs.

Entities:  

Year:  2005        PMID: 15841187      PMCID: PMC1076453          DOI: 10.4088/pcc.v07n0101

Source DB:  PubMed          Journal:  Prim Care Companion J Clin Psychiatry        ISSN: 1523-5998


  37 in total

Review 1.  Neuroanatomical hypothesis of panic disorder, revised.

Authors:  J M Gorman; J M Kent; G M Sullivan; J D Coplan
Journal:  Am J Psychiatry       Date:  2000-04       Impact factor: 18.112

2.  Panic in a general practice population: prevalence, psychiatric comorbidity and associated disability.

Authors:  H Birchall; S Brandon; N Taub
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2000-06       Impact factor: 4.328

3.  Early coadministration of clonazepam with sertraline for panic disorder.

Authors:  A W Goddard; T Brouette; A Almai; P Jetty; S W Woods; D Charney
Journal:  Arch Gen Psychiatry       Date:  2001-07

4.  Benzodiazepines: time for reassessment.

Authors:  D D Williams; A McBride
Journal:  Br J Psychiatry       Date:  1998-11       Impact factor: 9.319

Review 5.  New insights into the role of the GABA(A)-benzodiazepine receptor in psychiatric disorder.

Authors:  D J Nutt; A L Malizia
Journal:  Br J Psychiatry       Date:  2001-11       Impact factor: 9.319

6.  A double-blind, placebo-controlled, multicenter study with alprazolam and extended-release alprazolam in the treatment of panic disorder.

Authors:  J Pecknold; L Luthe; D Munjack; P Alexander
Journal:  J Clin Psychopharmacol       Date:  1994-10       Impact factor: 3.153

Review 7.  Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound.

Authors:  Guy Chouinard
Journal:  J Clin Psychiatry       Date:  2004       Impact factor: 4.384

8.  Double-blind, placebo-controlled study of a once-a-day, sustained-release preparation of alprazolam for the treatment of panic disorder.

Authors:  E Schweizer; W Patterson; K Rickels; M Rosenthal
Journal:  Am J Psychiatry       Date:  1993-08       Impact factor: 18.112

Review 9.  Pharmacotherapy of generalized anxiety disorder.

Authors:  Karl Rickels; Moira Rynn
Journal:  J Clin Psychiatry       Date:  2002       Impact factor: 4.384

10.  Risks and benefits of long-term benzodiazepine use.

Authors:  E H Uhlenhuth; H DeWit; M B Balter; C E Johanson; G D Mellinger
Journal:  J Clin Psychopharmacol       Date:  1988-06       Impact factor: 3.153

View more
  6 in total

1.  Alprazolam potentiates the antiaversive effect induced by the activation of 5-HT(1A) and 5-HT (2A) receptors in the rat dorsal periaqueductal gray.

Authors:  Valquíria Camin de Bortoli; Regina Lúcia Nogueira; Hélio Zangrossi
Journal:  Psychopharmacology (Berl)       Date:  2008-04-30       Impact factor: 4.530

2.  Combination treatment with benzodiazepines and SSRIs for comorbid anxiety and depression: a review.

Authors:  Boadie W Dunlop; Paula G Davis
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

Review 3.  [Early detection and treatment of panic disorder with or without agoraphobia: update].

Authors:  Guillaume Foldes-Busque; André Marchand; Pierre Landry
Journal:  Can Fam Physician       Date:  2007-10       Impact factor: 3.275

4.  Geriatric Depression and Inappropriate Medication: Benefits of Interprofessional Team Cooperation in Nursing Homes.

Authors:  Hana Vankova; Iva Holmerova; Ladislav Volicer
Journal:  Int J Environ Res Public Health       Date:  2021-11-26       Impact factor: 3.390

5.  Virtual Reality for Health Care Professionals During a Pandemic: A Pilot Program.

Authors:  Ivana T Croghan; Ryan T Hurt; Christopher A Aakre; Shawn C Fokken; Karen M Fischer; Stephanie A Lindeen; Darrell R Schroeder; Ravindra Ganesh; Karthik Ghosh; Brent A Bauer
Journal:  J Prim Care Community Health       Date:  2022 Jan-Dec

6.  Pharmacological management of panic disorder.

Authors:  Carlo Marchesi
Journal:  Neuropsychiatr Dis Treat       Date:  2008-02       Impact factor: 2.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.